Last 0.54 GBp
Change Today 0.00 / 0.00%
Volume 0.0
AKT On Other Exchanges
Symbol
Exchange
London
Munich
As of 12:00 PM 03/28/14 All times are local (Market data is delayed by at least 15 minutes).

ark therapeutics group plc (AKT) Snapshot

Open
--
Previous Close
0.54 GBp
Day High
--
Day Low
--
52 Week High
08/29/13 - 0.80 GBp
52 Week Low
11/6/13 - 0.28 GBp
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
0.0050 GBp
Shares Outstanding
209.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARK THERAPEUTICS GROUP PLC (AKT)

Related News

No related news articles were found.

ark therapeutics group plc (AKT) Related Businessweek News

No Related Businessweek News Found

ark therapeutics group plc (AKT) Details

Ark Therapeutics Group plc does not have significant operations. Prior to March 15, 2013, the company was engaged in the provision of contract development and manufacturing services to the pharmaceutical and biotech industry. Ark Therapeutics Group plc is based in London, the United Kingdom.

4 Employees
Last Reported Date: 04/29/14

ark therapeutics group plc (AKT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ark therapeutics group plc (AKT) Key Developments

Ark Therapeutics Group plc Announces Board Changes

Ark Therapeutics Group plc announced the retirement of Charles Spicer as a Non-Executive Director with effect from the Annual General Meeting. The Company also announced the appointment of Sue Steven as a Non-Executive Director of the company with effect from June 30, 2014. Mrs. Steven has worked with the company for over 10 years. Mrs. Steven currently acts as the Company Secretary and will continue in that role alongside her directorship. Prior to joining the company, Mrs. Steven held a number of managerial roles within a wide range of sectors, including legal, 3G mobile communications, computing and animal healthcare.

Ark Therapeutics Group plc, Annual General Meeting, Jun 30, 2014

Ark Therapeutics Group plc, Annual General Meeting, Jun 30, 2014., at 14:30 GMT Standard Time. Location: The offices of Ashurst LLP, Broadwalk House.

Ark Therapeutics Group plc Announces Audited Earnings Results for the Year Ended December 31, 2013

Ark Therapeutics Group plc announced audited earnings results for the year ended December 31, 2013. For the year, the company announced operating loss of GBP 1,095,000 compared to GBP 2,650,000 for the same period a year ago. Loss on ordinary activities before taxation was GBP 1,092,000 compared to GBP 2,729,000 for the same period a year ago. Loss on ordinary activities after taxation was GBP 1,092,000 compared to GBP 2,729,000 for the same period a year ago. Profit on ordinary activities after taxation, being retained profit for the year and total comprehensive income was GBP 1,101,000 or 0.5 pence per basic and diluted share compared to loss on ordinary activities after taxation, being retained profit for the year and total comprehensive loss of GBP 2,523,000 or 1.2 pence per basic and diluted share for the same period a year ago. Net cash used in operating activities was GBP 1,590,000 compared to GBP 46,000 for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKT:LN 0.54 GBp 0.00

AKT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AKT.
View Industry Companies
 

Industry Analysis

AKT

Industry Average

Valuation AKT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.3x
Price/Cash Flow 1.0x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARK THERAPEUTICS GROUP PLC, please visit www.arktherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.